The most expensive drug in the world is Lenmeldy, a one-time gene therapy with a list price of $4.25 million. Approved by the FDA in 2024, it treats metachromatic leukodystrophy, a rare inherited condition where a missing enzyme causes the protective coating around nerve cells to break down, leading to progressive loss of movement, speech, and cognitive function in young children. The treatment works by delivering a functional copy of the faulty gene into the patient’s own cells.
The 10 Most Expensive Drugs in the U.S.
The top of this list is dominated by one-time gene therapies for rare diseases. The prices below reflect the wholesale acquisition cost, which is essentially the manufacturer’s list price before insurance negotiations or rebates.
- Lenmeldy (metachromatic leukodystrophy): $4.25 million, one-time treatment
- Hemgenix (hemophilia B): $3.5 million, one-time treatment
- Elevidys (Duchenne muscular dystrophy): $3.2 million, one-time treatment
- Skysona (cerebral adrenoleukodystrophy): $3 million, one-time treatment
- Zynteglo (beta thalassemia): $2.8 million, one-time treatment
- Zolgensma (spinal muscular atrophy): $2.125 million, one-time treatment
- Myalept (generalized lipodystrophy): $1.3 million per year
- Danyelza (neuroblastoma): $1.2 million per year
- Zokinvy (progeria): $1.2 million per year
- Kimmtrak (uveal melanoma): $1.1 million per year
Notice the split: the six most expensive drugs are all one-time treatments. The remaining four cost over a million dollars every year for as long as the patient needs them, which can make their total lifetime cost rival or exceed even the priciest gene therapies.
Why Gene Therapies Cost Millions
Manufacturing a gene therapy is nothing like mass-producing a pill. These treatments use specially engineered viruses (stripped of their ability to cause illness) to carry corrected genes into a patient’s cells. Producing these viral carriers at pharmaceutical-grade quality is the single biggest expense, typically accounting for over 60% of the raw material costs. The specialized growth media, cell coatings, and signaling proteins needed during production can make up as much as 80% of total manufacturing costs in some processes.
Many of these therapies are autologous, meaning they’re built from the patient’s own cells. A blood sample is collected, the cells are genetically modified in a lab, and the corrected cells are infused back. Each dose is essentially a custom-manufactured product for one person. The expensive equipment used during production is tied up for that single patient and can’t be used for anything else until the batch is complete. Scaling up means buying more equipment, not running existing equipment faster.
On top of manufacturing, companies that develop treatments for ultra-rare diseases face a basic math problem: the research costs are enormous but the patient population is tiny. A drug that treats a condition affecting a few thousand people worldwide has to recover its development costs from a very small number of sales.
How Rare Disease Incentives Shape Pricing
The U.S. Orphan Drug Act was designed to make developing treatments for rare diseases financially viable when the market alone wouldn’t justify the investment. It offers manufacturers tax incentives, exemptions from certain FDA application fees, and seven years of market exclusivity for approved treatments. That exclusivity period means no competing version of the drug can be approved for the same condition during that window, giving the manufacturer a protected market.
A review by the HHS Office of Inspector General found that many of the highest-expenditure drugs covered by Medicare had qualified for these orphan drug incentives. The incentives work as intended in many cases, bringing treatments to patients who previously had none. But they also contribute to the environment where a single drug can carry a multimillion-dollar price tag with limited competitive pressure to bring costs down.
The Lifetime Cost Argument
Drug manufacturers often justify these prices by comparing a one-time treatment to decades of ongoing care. The math can be compelling. Take sickle cell disease as an example: Medicaid enrollees with the condition had average annual spending of $22,600 in 2021, more than double the average for all Medicaid patients. For those with the most severe cases, costs reached up to $200,000 per year, driven by repeated hospitalizations and an average of 25 emergency room visits annually. Those costs only climb as patients age.
Two gene therapies for sickle cell disease, each priced above $2 million, are now available. A Congressional Budget Office analysis found that if these treatments prove to be a lasting cure, patients and insurers would face steep upfront costs but accumulate savings over time through reduced hospitalizations, fewer emergency visits, and less need for ongoing medication. The catch is that these savings take years to materialize, often beyond the standard 10-year budget window that policymakers use to evaluate costs. And the therapies are still too new to know for certain whether the benefits hold for a full lifetime.
How Patients Actually Access These Drugs
Very few patients pay these prices out of pocket. Most access comes through insurance, and a growing number of payers are negotiating creative payment structures to manage the financial shock. The most notable development is an outcomes-based model led by the Centers for Medicare and Medicaid Services. Launched in 2025, it’s the first time the federal government has negotiated directly with gene therapy manufacturers on behalf of state Medicaid programs.
Under this model, participating states receive guaranteed discounts upfront. If a therapy fails to deliver on its promised results, the manufacturer owes additional rebates. The program is voluntary for both states and manufacturers, with flexible start dates and federal support of up to $9.55 million per state to help with tracking patient outcomes and implementation. The approach represents a fundamental shift: rather than simply paying a list price, the government is tying what it pays to whether the treatment actually works.
Private insurers have adopted similar strategies, spreading payments over several years and building in performance guarantees. Some manufacturers also run patient assistance programs that cover portions of the cost for uninsured or underinsured patients, though the specifics vary widely by drug and company.
What Makes Hemgenix and Elevidys Different
Hemgenix, the second most expensive drug at $3.5 million, treats hemophilia B, a condition where the blood doesn’t clot properly due to a shortage of a specific clotting protein. The treatment delivers a gene that instructs liver cells to produce that protein on their own. For patients who previously needed regular infusions of clotting factor to prevent dangerous bleeding episodes, a single intravenous dose can potentially replace a lifetime of treatment.
Elevidys, priced at $3.2 million, targets Duchenne muscular dystrophy, a progressive muscle-wasting disease that primarily affects boys. It’s currently approved only for children aged 4 to 5 who can still walk and who don’t carry certain genetic mutations that would interfere with the therapy. That narrow approval window means timing is critical for families. The treatment delivers a shortened version of the gene responsible for producing a key muscle protein, aiming to slow or halt the disease’s progression during a window when intervention can still make a meaningful difference.